Long-term treatment of rats with haloperidol: Lack of an effect on brain N-acetyl aspartate levels

Neuropsychopharmacology

Volumn 31, Issue 4, 2006, Pages 751-756

  Bustillo, Juan ^a,b,f   Barrow, Ranee ^a   Paz, Rodrigo ^b,e   Tang, Jennifer ^c   Seraji Bozorgzad, Navid ^c   Moore, Gregory J ^d   Bolognani, Federico ^b   Lauriello, John ^a   Perrone Bizzozero, Nora ^b   Galloway, Matthew P ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PENN STATE COLLEGE OF MEDICINE   (United States)

^e UNIVERSIDAD DIEGO PORTALES   (Chile)

^f UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antipsychotic; Glutamate; H MRS; Haloperidol; N acetyl aspartate; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT;

AMINO ACID BRAIN LEVEL; AMYGDALOID NUCLEUS; ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CINGULATE GYRUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS STRIATUM; FACTORIAL ANALYSIS; FRONTAL CORTEX; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIPPOCAMPUS; LONG TERM CARE; MALE; METABOLITE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PUNCH BIOPSY; RAT; RECEPTOR BLOCKING; SCHIZOPHRENIA; TEMPORAL CORTEX;

ANIMALS; ASPARTIC ACID; BRAIN; BRAIN CHEMISTRY; DOPAMINE ANTAGONISTS; DRUG ADMINISTRATION SCHEDULE; GLUTAMIC ACID; GLUTAMINE; HALOPERIDOL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33645026826     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300874     Document Type: Article

References (29)

1. Andreassen O, Aamo TO, Jorgensen HA (1996). Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 119: 751-757.
2. Andreassen O, Jorgensen H (1995). The rat model of tardive dyskinesia: relationship between vacuous chewing movements and gross motor activity during acute and long-term haloperidol treatment. Life Sci 57: 2263-2272.
3. Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF et al (2001). The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 49: 39-46.
4. Bustillo J, Lauriello J, Rowland L, Jung R, Petropoulus H, Hart B et al (2001). Effects of chronic haloperidol and clozapine treatments on frontal and caudate brain neurochemistry in schizophrenia. Psychiatry Res Neuroimaging 107/3: 135-149.
5. Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulos H, Hammond R et al (2002). Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 58: 313-321.
6. Bustillo J, Wolff C, Myers-y-Gutierrez A, Dettmer T, Cooper T, Allan A et al (2004). Treatment of rats with antipsychotic drugs: lack of an effect on N acetyl-aspartate levels. Schizophr Res 66: 31-39.
7. Chakos M, Lieberman J, Alvir J, Bilder R, Ashtari M (1995). Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 345: 456-457.
8. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A et al (1997). Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 94: 6408-6413.
9. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH (1996). Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 6: 345-352.
10. Florian C, Williams S, Bhakoo K, Noble M (1996). Regional and developmental variations in metabolite concentration in the rat brain and eye: a study using H-NMR spectroscopy and high performance liquid chromatography. Neurochem Res 21: 1065-1074.
11. Galloway MP, Wolf ME, Roth RH (1986). Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. J Pharmacol Exp Ther 236: 689-698.
12. Grimm JW, Kruzich PJ, See RE (1998). Emergence of oral and locomotor activity in chronic haloperidol-treated rats following cortical N-methyl-D-aspartate stimulation. Pharmacol Biochem Behav 60: 167-173.
13. Holcomb HH, Cascella NG, Thake GK, Medoff DR, Dannals RF, Tamminga CA (1996). Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry 153: 41-49.
14. Keshavan MS, Bagwell WW, Haas GL, Sweeney JA, Schooler NR, Pettegrew JW (1994). Changes in caudate volume with neuroleptic treatment (letter). Lancet 344: 1434.
15. Koller KJ, Zaczek R, Coyle JT (1984). N-acetyl-aspartyl-glutamate: regional levels in rat brain and the effects of brain lesions as determined by a new HPLC method. J Neurochem 43: 1136-1142.
16. Lindquist DM, Hawk RM, Karson CN, Komoroski RA (2000). Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn Reson Med 43: 355-358.
17. Meshul C, Bunker G, Mason J, Allen C, Janowsky A (1996). Effects of subchronic clozapine and haloperidol on striatal glutamatergic synapses. J Neurochem 67: 1965-1973.
18. Moffet JR, Namdoori MAA (1995). Differential distribution of N-acetylapartylglutamate and N-acetylapartate immunoreactivities in rat forebrain. J Neurocytol 24: 409-433.
19. Moore GJ, Galloway MP (2002). Magnetic resonance spectroscopy: neurochemistry and treatment effects in affective disorders. Psychopharmacol Bull 36: 5-23.
20. Palao D, Arauxo A, Brunet M, Bernardo M, Haro J, Ferrer J et al (1994). Haloperidol: therapeutic window in schizophrenia. J Clin Psychopharmacol 14: 303-310.
21. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego. pp 256.
22. 1H NMR spectra of the rat brain. J Magn Res 141: 104-120.
23. Provencher S (1993). Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
24. 1H-MRS) studies of schizophrenia. Semin Clin Neuropsychiatry 6: 121-130.
25. See RE, Chapman MA, Klitenick MA (1992). Chronic neuroleptic administration decreases extracellular GABA in the nucleus accumbens but not in the caudate-putamen of rats. Brain Res 588: 177-180.
26. Theberge J, Al-Semaan Y, Williamson P, Menon RS, Neufeld RW, Rajakumar N et al (2003). Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0 T proton MRS. Am J Psychiatry 160: 2231-2233.
27. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159: 1944-1946.
28. 1H-NMR spectroscopy. Magn Res Med 50: 24-32.
29. Tsai G, Coyle JT (1995). N-acetylaspartate in neuropsychiatric disorders. Prog Neurobiol 46: 531-540.